Literature DB >> 8568547

Tissue penetration and pulmonary disposition of tobramycin.

T Mazzei1, A Novelli, F De Lalla, E Mini, P Periti.   

Abstract

The pharmacokinetics of tobramycin, including the penetration into suction blister fluid (SBF), has been investigated in 12 patients with a mean age of 69.8 +/- 4.6 yrs, after a single i.m. administration of either 150 or 300 mg. Tobramycin demonstrated a concentration-independent pharmacokinetics and a high diffusion into the extravascular compartment with a penetration index (obtained by the SBF and serum AUC ratio) of 135% with no significant differences between the two groups of patients. Tobramycin was also administered as a single or multiple i.m. dose of 300 mg in 10 intensive care patients undergoing fiberoptic bronchoscopy for diagnostic purposes. The aminoglycoside mean concentration 6h after the single or last administration ranged from 5.3 to 5.5 mg/l and from 3.0 to 3.3 mg/l in alveolar lining fluid (ALF) and macrophages (AM), respectively, thus demonstrating that the once-daily dosage schedule leads to high and persistent levels in the bronchial alveolar tree, exceeding the minimum inhibitory concentrations in vitro for susceptible respiratory pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568547     DOI: 10.1179/joc.1995.7.4.363

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

Review 1.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

2.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 3.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

4.  Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling.

Authors:  Bruna Bernar Dias; Fernando Carreño; Victória Etges Helfer; Priscila Martini Bernardi Garzella; Daiane Maria Fonseca de Lima; Fabiano Barreto; Bibiana Verlindo de Araújo; Teresa Dalla Costa
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

5.  Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients.

Authors:  Emmanuel Boselli; Dominique Breilh; Sarah Djabarouti; Christian Guillaume; Thomas Rimmelé; Jean-Baptiste Gordien; Fabien Xuereb; Marie-Claude Saux; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.